We have a strong history of delivering biological medicines for immunological diseases and we continue to build a pipeline of exciting, new biotechnological products, while expanding into small-molecule oral medications and broadening our disease focus in autoimmune, inflammatory and pulmonary diseases.  Through our ongoing efforts in discovery, biomarkers, clinical research and external innovation, we are poised for continued leadership and growth, bringing transformational medicines to patients and healthcare providers around the world.